Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228953 · ClinicalTrials.gov registry record · NA
Pharmacogenomic Testing in Major Depressive Disorder
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT03228953 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 38 participants.
The verdict
NCT03228953, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder. Participants will be randomly assigned to two groups: pharmacogenomic-guided therapy group (guided group) and treatment as usual group (TAU group). The primary hypothesis is the pharmacogenomic-guided treatment group will demonstrate significantly higher percent improvement in depression score compared to treatment-as-usual group.
Interventions
- OTHER Pharmacogenomic testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-07-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228953
The ClinicalTrials.gov registry entry for NCT03228953 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenomic testing is the first listed.
NCT03228953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03228953 about?
NCT03228953 is a clinical study titled "Pharmacogenomic Testing in Major Depressive Disorder". This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder. Participants will be randomly assigned to two groups: pharmacogenomic-guided therapy group (guided group) and treatment a...
What is the current status of trial NCT03228953?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2017-08-01. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT03228953?
The interventions under investigation include: Pharmacogenomic testing (OTHER).
Who is sponsoring clinical trial NCT03228953?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.